

## Special Issue

# Pharmaceutical and Cellular Strategies to Treat GVHD

### Message from the Guest Editors

Graft-versus-host disease (GVHD) is a systemic disorder characterized by inflammation in different organs, with the specificity of epithelial cell apoptosis and crypt drop out. The Special Issue Pharmaceutical and Cellular Strategies to Treat GVHD will present reviews and original papers describing novel drugs and therapeutics up-to-date that hold promise for improved prevention and treatment of GVHD. The suggested papers will discuss different approaches to improve pharmaceutical strategies for prevention and treatment of GVHD (comparing methods of GVHD prevention and lymphodepletion); outline new therapeutic approaches involving innovative agents and hematopoietic stem-cell transplantation (HSCT) for pathogenetic GVHD therapy; compare the effectiveness of chemotherapy and HSCT, including promising technologies that may improve the results of treatment of patients with hematologic malignancies. Keywords: GVHD, Autoimmune Diseases, MSC, HSCT, Oncohematology, Prevention, Treatment, Chemotherapy

### Guest Editors

Prof. Dr. Mikhail Kiselevsky

Dr. Lina Hsiu Kim Lim

Prof. Svetlana Varfolomeeva

Dr. Kirill Kirgizov

### Deadline for manuscript submissions

closed (20 December 2021)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/66874](https://mdpi.com/si/66874)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)